Conjugated estrogens/trimegestone - Wyeth

Drug Profile

Conjugated estrogens/trimegestone - Wyeth

Alternative Names: Premarin®/Trimegestone; Trimegestone/conjugated estrogens; Trimegestone/Premarin®

Latest Information Update: 16 Jul 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma; Wyeth
  • Developer Wyeth
  • Class Estradiol congeners; Norpregnadienes; Osteoporosis therapies
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 31 Dec 2001 Phase-III clinical trials in Postmenopausal osteoporosis in USA (PO)
  • 31 Aug 2001 Phase-III clinical trials in Menopausal syndrome in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top